RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 865-877

  Min, Ahrum ^a   Im, Seock Ah ^a,b   Yoon, Young Kwang ^a   Song, Sang Hyun ^a   Nam, Hyun Jin ^a   Hur, Hyung Seok ^a   Kim, Hwang Phill ^a   Lee, Kyung Hun ^a,b   Han, Sae Won ^a,b   Oh, Do Youn ^a,b   Kim, Tae You ^a,b,d   O'Connor, Mark J ^e   Kim, Woo Ho ^a,c   Bang, Yung Jue ^a,b  

^a Seoul National University   (South Korea)

^b Departments of Internal Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MEMBRANE PROTEIN; OLAPARIB; RAD51C PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; COMPETITIVE INHIBITION; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG SENSITIVITY; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOLECULAR TARGETED THERAPY; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RADIATION-SENSITIZING AGENTS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879308097     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0950     Document Type: Article

References (37)

1. McCabe N. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
2. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7.
3. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
4. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376: 235-44.
5. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor ola-parib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
6. Plummer ER, Calvert H. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res 2007;13: 6252-6.
7. Johnson N, Li Y-C, Walton ZE, Cheng KA, Li D, Rodig SJ, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011;17:875-82.
8. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-11.
9. Smeenk G, de Groot AJ, Romeijn RJ, van Buul PP, Zdzienicka MZ, Mullenders LH, et al. Rad51C is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability. Mutat Res 2010;689:50-8.
10. Kuznetsov SG, Haines DC, Martin BK, Sharan SK. Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice. Cancer Res 2009;69:863-72.
11. Kuznetsov S, Pellegrini M, Shuda K, Fernandez-Capetillo O, Liu Y, Martin BK, et al. RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females. J Cell Biol 2007;176:581-92.
12. French CA. Role of mammalian RAD51L2 (RAD51C) in recombination and genetic stability. J Biol Chem 2002;277:19322-30.
13. Badie S, Liao C, Thanasoula M, Barber P, Hill MA, Tarsounas M. RAD51C facilitates checkpoint signaling by promoting CHK2 phos-phorylation. J Cell Biol 2009;185:587-600.
14. Rodrigue A, Lafrance M, Gauthier MC, McDonald D, Hendzel M, West SC, et al. Interplay between human DNA repair proteins at a unique double-strand break in vivo. Embo J 2006;25:222-31.
15. 2-phase cells. J Biol Chem 2004;279:42313-20.
16. Ku JL, Park JG. Biology of SNU cell lines. Cancer Res Treat 2005; 37:1-19.
17. Ahn SH, Son BH, Yoon K-S, Noh D-Y, Han W, Kim S-W, et al. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett 2007;245:90-5.
18. Nam H-J, Kim H-P, Yoon Y-K, Song S-H, Min A-R, Han S-W, et al. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Invest New Drugs 2012;30:2148-60.
19. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AOH, Zander SAL, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105: 17079-84.
20. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13: 1383-8.
21. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AOH, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009;69:3850-5.
22. Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, et al. The polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia 2005;7:1011-9.
23. Zeidler M, Kleer CG. The polycomb group protein enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol 2006;37:219-23.
24. Stefansson OA, Esteller M. EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells. Breast Cancer Res 2011;13:309.
25. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
26. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
27. Abe K, Osakabe K, Nakayama S, Endo M, Tagiri A, Todoriki S, et al. Arabidopsis RAD51C gene is important for homologous recombination in meiosis and mitosis. Plant Physiol 2005;139:896-908.
28. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010;42:406-9.
29. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Nieder-acher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010;42:410-4.
30. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011;43:879-82.
31. Liu Y, Tarsounas M, O'Regan P, West SC. Role of RAD51C and XRCC3 in genetic recombination and DNA repair. J Biol Chem 2007;282: 1973-9.
32. Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly (adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010;28:e563-4.
33. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011;103:334-46.
34. Horton JK, Stefanick DF, Zeng JY, Carrozza MJ, Wilson SH. Require-ment for NBS1 in the S phase checkpoint responseto DNAmethylation combined with PARP inhibition. DNA Repair (Amst) 2011;10:225-34.
35. Ibragimova I, Cairns P. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol 2011;780:277-91.
36. Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011;30:3391-403.
37. Bae YK, Shim YR, Choi JH, Kim MJ, Gabrielson E, Lee SJ, et al. Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat 2005;37:233-40.